GlobeNewswire Press

31. Cambrex Completes Acquisition Of CDMO Avista Pharma Solutions 1/2/2019

    Cambrex Corporation (NYSE: CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), and finished dosage forms, today announced that it has completed the acquisition of Avista Pharma Solutions (“Avista”), a contract development, manufacturing, and testing organization, from Ampersand Capital Partners.

32. Orchard Therapeutics To Invest $150M Into New Gene Therapy Manufacturing Facility In California 12/13/2018

    Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced that it has signed a long-term lease agreement to build-out a gene therapy manufacturing facility in Fremont, California.

33. CDMO Recro Opens GMP Development And High Potency Product Services Facility 10/1/2018

    Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced the opening of an expanded 24,000 square foot GMP development and high potency product services facility in Gainesville, GA.

34. Cambrex To Expand Operations To Establish Center Of Excellence For API Clinical Supply And Process Development In North Carolina 9/25/2018

    Cambrex Corporation (NYSE: CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), and finished dosage forms today announced that it is to establish a center of excellence for API clinical supply and process development at its site in High Point, North Carolina.

35. Cambrex Expanding High Potency API Manufacturing Facilities In NC And Iowa 5/15/2018

    Cambrex Corporation (NYSE:CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that it has completed a pilot plant expansion at its High Point, NC facility with the installation and commissioning of a fourth reactor suite, increasing the site's reactor capacity by around 30%.

36. Arcturus Therapeutics Announces Strategic Collaboration With Johnson & Johnson Innovation To Discover And Develop RNA Medicines 10/19/2017

    Arcturus Therapeutics, Inc., a leading RNA medicines company, announced today that it has entered into a research collaboration and worldwide license agreement with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

37. Sanofi To Invest €170M In New Vaccine Manufacturing Facility In France 10/12/2017

    Sanofi is investing €170 million to expand a vaccine manufacturing site in Val de Reuil, France.

38. Sonoco ThermoSafe Launches Revolutionary Design For Temperature-Sensitive Bulk Air Shipments 1/19/2016

    Sonoco ThermoSafe, a unit of Sonoco (NYSE:SON) and a leading global provider of temperature assurance packaging, has launched one of its most innovative bulk temperature-controlled solutions to optimize air shipments of temperature-sensitive biologics and pharmaceutical products for durations exceeding five days.

39. Bavarian Nordic Announces Initiation Of Safety And Immunogenicity Study Of Ebola Vaccine Regimen In Sierra Leone 10/9/2015

    Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today the initiation of a new clinical study of the Ebola prime-boost vaccine regimen that combines Bavarian Nordic's MVA-BN® Filo vaccine with the Ad26.ZEBOV vaccine from Crucell Holland B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen).

40. Novavax To Review Recent Findings From Vaccine Programs At World Vaccine Congress And Expo In Washington, DC 4/15/2013

    Novavax, Inc. (Nasdaq:NVAX) announced today that it will review recent clinical results from the company's vaccine development programs at the World Vaccine Congress and Expo this week in Washington, DC.